We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current VKTX market cap is 2.8B. The company's latest EPS is USD -0.9796 and P/E is -25.51.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -29.29M | -34.07M | -34.05M | -36.56M | -46.24M |
| Net Income | -24.61M | -27.36M | -22.25M | -24.94M | -35.42M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -42.66M | -55.68M | -70.36M | -100.83M | -150.92M |
| Net Income | -39.5M | -54.99M | -68.87M | -85.9M | -109.96M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 368.49M | 967.52M | 946.84M | 937.89M | 908.32M |
| Total Liabilities | 20.07M | 33.63M | 25.86M | 26.44M | 28.04M |
| Total Equity | 348.42M | 933.89M | 920.98M | 911.45M | 880.28M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 256.5M | 210.66M | 168.53M | 368.49M | 908.32M |
| Total Liabilities | 12.16M | 8.78M | 23.21M | 20.07M | 28.04M |
| Total Equity | 244.34M | 201.88M | 145.32M | 348.42M | 880.28M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -73.38M | -6.13M | -34.65M | -56.61M | -87.79M |
| Investing | -179.09M | -459.79M | -585.85M | -559.95M | -553.37M |
| Financing | 271.38M | 606.04M | 608.94M | 611.46M | 612.46M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -21.78M | -47.59M | -48.4M | -73.38M | -87.79M |
| Investing | 41.57M | 37.96M | 54.75M | -179.09M | -553.37M |
| Financing | 950k | 6.88M | 4.16M | 271.38M | 612.46M |
| Market Cap | 2.8B |
| Price to Earnings Ratio | -25.51 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 105.13 |
| Price to Book Ratio | 3.19 |
| Dividend Yield | - |
| Shares Outstanding | 112.25M |
| Average Volume (1 week) | 3.5M |
| Average Volume (1 Month) | 4.63M |
| 52 Week Change | -60.40% |
| 52 Week High | 81.86 |
| 52 Week Low | 18.92 |
| Spread (Intraday) | 0.4 (1.6%) |
| Company Name | Viking Therapeutics Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.vikingtherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
